<SEC-DOCUMENT>0001437749-26-019479.txt : 20260604
<SEC-HEADER>0001437749-26-019479.hdr.sgml : 20260604
<ACCEPTANCE-DATETIME>20260604085021
ACCESSION NUMBER:		0001437749-26-019479
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20260630
FILED AS OF DATE:		20260604
DATE AS OF CHANGE:		20260604

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ALTERITY THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001131343
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-49843
		FILM NUMBER:		261063328

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		LEVEL 3, 460 BOURKE STREET
		CITY:			MELBOURNE
		PROVINCE COUNTRY:   	C3
		BUSINESS PHONE:		61 3 9349 4906

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		LEVEL 3, 460 BOURKE STREET
		CITY:			MELBOURNE
		PROVINCE COUNTRY:   	C3

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PRANA BIOTECHNOLOGY LTD
		DATE OF NAME CHANGE:	20010105
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>athe20260604_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<html><head>
	<title>athe20260604_6k.htm</title>
	<!-- Generated by ThunderDome Portal - 6/4/2026 1:52:22 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Washington, D.C. 20549</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>FORM 6-K</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>REPORT OF FOREIGN PRIVATE ISSUER</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PURSUANT TO RULE 13a-16 OR 15d-163</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>UNDER THE SECURITIES EXCHANGE ACT OF 1934</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>For the month of June&nbsp;2026</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Alterity Therapeutics Limited</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Name of Registrant)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Level 15, 500 Collins Street, Melbourne, Victoria 3000 Australia</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Address of Principal Executive Office)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Form 20-F &#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F &#9744;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b>This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. </b><a href="http://www.sec.gov/Archives/edgar/data/1131343/000121390020040485/ea130838-s8_alteritytherape.htm" style="-sec-extract:exhibit;"><b><u>333-251073</u></b></a><b>, </b><a href="http://www.sec.gov/Archives/edgar/data/1131343/000121390020027969/ea127207-s8_alteritytherap.htm" style="-sec-extract:exhibit;"><b><u>333-248980</u></b></a><b> and </b><a href="http://www.sec.gov/Archives/edgar/data/1131343/000114420418063081/tv508429_s-8.htm" style="-sec-extract:exhibit;"><b><u>333-228671</u></b></a><b>) and our Registration Statements on Form F-3 (Files No. </b><a href="http://www.sec.gov/Archives/edgar/data/1131343/000101376223000033/ea185947-f3_alteritytherape.htm" style="-sec-extract:exhibit;"><b><u>333-274816</u></b></a><b>, </b><a href="http://www.sec.gov/Archives/edgar/data/1131343/000121390020044324/ea132148-f3_alteritytherape.htm" style="-sec-extract:exhibit;"><b><u>333-251647</u></b></a><b>, </b><a href="http://www.sec.gov/Archives/edgar/data/1131343/000114420419025615/tv521271_f3.htm" style="-sec-extract:exhibit;"><b><u>333-231417</u></b></a><b> and </b><a href="http://www.sec.gov/Archives/edgar/data/1131343/000121390020036934/ea129831-f3_alteritytherap.htm" style="-sec-extract:exhibit;"><b><u>333-250076</u></b></a><b>)</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<div contenteditable="false" data-applyto="p" data-auto-pgnum="start" data-displaynum="1" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="" data-startnum="1" data-suffix="" data-textalign="center">&nbsp;</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>ALTERITY THERAPEUTICS LIMITED</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(a development stage enterprise)</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The following exhibits are submitted:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">99.1</p>
			</td>
			<td style="width: auto;"><a href="ex_972197.htm" style="-sec-extract:exhibit;">Share Consolidation Effective, Trading Under ATHDA</a></td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="1" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">1</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>SIGNATURE</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:auto;">&nbsp;</td>
			<td colspan="2" style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Alterity Therapeutics Limited</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:32.1%;">&nbsp;</td>
			<td style="vertical-align:top;width:2.1%;">&nbsp;</td>
			<td style="vertical-align:top;width:19.2%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:auto;">&nbsp;</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By:</p>
			</td>
			<td style="vertical-align: top; width: auto; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Julian Babarczy</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:auto;">&nbsp;</td>
			<td style="vertical-align:top;width:auto;">&nbsp;</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Julian Babarczy</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:auto;">&nbsp;</td>
			<td style="vertical-align:top;width:auto;">&nbsp;</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chairman</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date: June 4, 2026</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="2" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">2</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex_972197.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html><head>
	<title>ex_972197.htm</title>
	<!-- Generated by ThunderDome Portal - 6/4/2026 1:56:58 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 99.1</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="logo.jpg" src="logo.jpg"></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>Share Consolidation and ASX Code</b></p>

<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><i>&#8210; Alterity shares to trade under the temporary ticker of </i>&#8220;<i>ATHDA</i>&#8221;<i> until 12 June </i>&#8210;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b>MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA </b>&#8211;<b> 4 June 2026:</b>&nbsp; <u>Alterity Therapeutics</u> (ASX: ATH, NASDAQ: ATHE) (&#8220;Alterity&#8221; or &#8220;the Company&#8221;), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, advises that, further to shareholder approval received at the Extraordinary General Meeting on 29 May, 2026, the consolidation of the Company&#8217;s share capital on a 1 for 50 basis is now being actioned.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">From 3 June 2026 until the close of trading on 11 June 2026, trading in the Company&#8217;s securities takes place on a post-consolidation and deferred settlement basis under a temporary ASX code &#8220;<b>ATHDA</b>&#8221;, with a record date of 4 June 2026.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Additionally, the Company&#8217;s &#8220;ATHO&#8221; and &#8220;ATHOA&#8221; listed options will trade under temporary codes &#8220;ATHDB&#8221; and &#8220;ATHDC&#8221; respectively on a deferred settlement basis.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Normal trading (on a T+2 settlement basis) commences 12 June under ASX code &#8220;ATH&#8221;.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Shareholders are reminded that the number of shares they hold has been reduced in accordance with the 1 for 50 consolidation ratio, with any fractional entitlements rounded up to the nearest whole number (to a minimum of 1 security).&nbsp; The Company&#8217;s share price has adjusted accordingly.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">For more information, please refer to the Company&#8217;s ASX Announcements on Consolidation and Notice of General Meeting released to the ASX.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b>About Alterity Therapeutics Limited </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living&nbsp;with neurodegenerative diseases. The Company is focused on developing disease modifying therapies in Multiple System Atrophy (MSA) and related Parkinsonian disorders. Alterity is preparing to initiate a Phase 3 pivotal trial in MSA, a rare and rapidly progressive disease. ATH434, the Company&#8217;s lead asset, has demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with MSA. Alterity has further reported positive data in its open label Phase 2 clinical trial in participants with advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company&#8217;s website at <u>www.alteritytx.com</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b>Authorization &amp; Additional information</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b>Contacts:</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b>Investors</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Elyse Shapiro</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><u>ir@alteritytx.com</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Remy Bernarda</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Investor Relations Advisory Solutions</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><u>ir@alteritytx.com</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">+1 (415) 203-6386</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b>Media</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Casey McDonald</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Tiberend Strategic Advisors, Inc.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">cmcdonald@tiberend.com</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">+1 (646) 577-8520</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  U -P# 2(  A$! Q$!_\0
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M*G>'?%NI^ M)\1:=!X/O([.[&K0)&9'<,5*;6/'RYKZH#<<D9[TIQY-& M%
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MRRQ16MR^W[%K=IG?#MZ9DC##/<JHK>M#VE#5W:*.H_X/%S_QDI\ ?^P==?\
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M7 9\._V9M$^%WQ[^('Q#LKK49M7^)'V$:A#-(#!!]DB:./RQCC(/->7^(_\
M@G-92_%77O&'@3XB^/OA>/%]XNH>)-*T&YB^PZS<#;NGV2(QAE=0%9XR":**
MI,#U#XY_!G4OC?X,L=.TGQQXI\!WUK*EU#J6BR1&8@#:8I4E1DE0YR0R]:\K
M^$7_  3-^&?P8T;4K:_@U7Q?K6MZE-K&JZQJ-UY-Q?W4P7>Y2 )&O"KPJ@<4
(45<-78:1_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
